title: Update on atrial fibrillation.
abstract: Atrial fibrillation (AF) is the most common arrhythmia with a substantial effect on individual morbidity and mortality as well as healthcare expenditure. The management of AF is complex and fraught with many uncertain and contentious issues. We have seen substantial progress in AF management in the last two decades including better understanding of the epidemiology, genomics, monitoring, drug and non-pharmacological treatment of the arrhythmia, its complications and stroke risk reduction. In this review, we present a comprehensive discussion on AF with emphasis on most recent updates.
authors: Lankenau Medical Center, Lankenau Institute of Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096.
authors: Amanulla
authors: A
authors: Khaji
authors: Lankenau Medical Center, Lankenau Institute of Medical Research, 100 Lancaster Avenue, Wynnewood, PA 19096; Jefferson Medical College, Thomas Jefferson University, Wynnewood, PA. Electronic address: KoweyP@MLHS.ORG.
authors: Peter R
authors: PR
authors: Kowey
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D020517:Atrial Appendage / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D006328:Cardiac Catheterization / Q000295:instrumentation; D017115:Catheter Ablation / Q000009:adverse effects; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors
keywords: Ablation; Antiarrythmic drugs; Anticoagulation; Atrial fibrillation; Stroke risk